Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-13

Clinical Trial Update: Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tradipitant for treatment-resistant pruritus in atopic dermatitis has completed, with the results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tradipitant (tradipitant)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-06-13